Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How Will the Non-Alcoholic Steatohepatitis Treatment Market’s Growth Rate Evolve Over the Forecast Period to 2034?
The market for non-alcoholic steatohepatitis treatments has seen a significant rise in its size in the recent past. It is projected to expand from a value of $2.6 billion in 2024 to an impressive $3.6 billion in 2025, with a compound annual growth rate (CAGR) of 38.5%. The growth noted in the historical period can be identified to the increasing cases of NASH, improving awareness and diagnoses, changes in lifestyle and obesity outbreak, advancements in clinical research, access and improvements to healthcare infrastructure, regulatory backing, and clinical trial developments.
In the forthcoming years, the market size for non-alcoholic steatohepatitis treatment is forecasted to witness substantial growth, ballooning to $13.83 billion by 2029 with a compound annual growth rate (CAGR) of 40.0%. This upswing during the forecast period is tied to progress in drug innovation, heightened understanding of the disease, burgeoning prevalence and risk factor, coupled with a transition to personalized medicine. In the same timeline, key developments are set to be patient-centric methodologies, breakthroughs in technology, focused therapies, regulatory framework, and improvements in scientific research.
What Key Drivers Are Accelerating the Growth of the non-alcoholic steatohepatitis treatment Market During the Forecast Period?
The escalation in the occurrence of insulin resistance has become a driving force for the expansion of the non-alcoholic steatohepatitis treatment market. Insulin resistance transpires when the body’s muscles, fat, and liver cells fail to adequately respond to insulin, impeding the easy absorption of glucose from the bloodstream, hence instigating high blood sugar levels. Requirements for insulin resistance are tied to poor lifestyle habits, excessive intake of sugar, and inherited traits. The growing prevalence of diabetes and various liver-related health issues have amplified the demand for insulin resistance treatment, primarily managed by non-alcoholic steatohepatitis care. For example, a report in January 2022 by the International Diabetes Federation, a diabetes community based in Belgium, indicated that diabetes impacts 537 million individuals aged 20-79, equivalent to one in every ten people. This figure is projected to rise to 643 million by 2030 and 783 million by 2045. Additionally, a forecast in January 2024 by the American Cancer Society, a U.S. nonprofit cancer advocacy group, predicted that new liver cancer incidences would amount to 41,630 in 2024, an increase from 41,210 in 2023. Consequently, the surge in insulin resistance, linked with numerous liver issues and diabetes, is catalyzing the growth of the non-alcoholic steatohepatitis treatment market.
Request Your Free Non-Alcoholic Steatohepatitis Treatment Market Report Sample Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
Who Are the Influential Players Reshaping the Non-Alcoholic Steatohepatitis Treatment Market Landscape?
Major companies operating in the non-alcoholic steatohepatitis treatment market are:
• AstraZeneca PLC_x000D_
• Galmed Pharmaceuticals Ltd._x000D_
• Genfit S.A._x000D_
• Zydus Cadila Healthcare Limited_x000D_
• Bristol-Myers Squibb Company_x000D_
What New and Evolving Trends Are Having a Lasting Impact on the Non-Alcoholic Steatohepatitis Treatment Market?
The trend of non-alcoholic steatohepatitis (NASH) drug development is becoming increasingly prevalent in the non-alcoholic steatohepatitis treatment market. Numerous enterprises are focusing their resources on inventing novel drugs for liver conditions, with an emphasis on minimising the drugs’ side effects. For example, in May 2022, the American pharmaceutical and biotechnology business, Pfizer Inc., was awarded a fast-track designation grant by the U.S. Food and Drug Administration (FDA) to expedite the progression of the NASH drug, ervogastat and clesacostat. Pfizer’s investigational combination therapy, ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi), designed to treat NASH with liver fibrosis, falls under this Fast Track process.
Pre-order Your Report for Quick and Easy Delivery!
What Are the Core Segments of the Non-Alcoholic Steatohepatitis Treatment Market, and How Do They Contribute to Growth?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor-Based Treatments
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies
Which Geographic Locations Are Critical to the Growth of the Non-Alcoholic Steatohepatitis Treatment Market?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Defining Aspects of the Non-Alcoholic Steatohepatitis Treatment Market Landscape?
The non-alcoholic steatohepatitis treatment refers to a treatment used in steatohepatitis by maintaining a healthy diet, control of blood sugar, loss of body weight and fat. It is a treatment type for liver disease in which people who drink little, or no alcohol develop fatty livers. This causes liver cell destruction and inflammation, which can lead to cirrhosis.
Browse Through More Similar Reports By The Business Research Company:
Protein Supplements Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/protein-supplements-global-market-report
Nutritional Analysis Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/nutritional-analysis-global-market-report
Probiotics Dietary Supplements Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
